Short answer
Dyne Therapeutics, Inc. (DYN) filed its Q1 2026 10-Q quarterly report on May 11, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$121M
- −4.8% YoY
- EPS (diluted)
- −$0.73
- +30.5% YoY
Source: XBRL data from the Dyne Therapeutics, Inc. (DYN) Q1 2026 10-Q on SEC EDGAR. USD.
Dyne Therapeutics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0 in both quarters; no product sales or other revenue generated
- Net loss $120.9M vs $115.4M YoY; operating loss $125.3M vs $122.4M
- Best performer z-rostudirsen R&D $37.7M, up $16.7M; z-basivarsen $14.8M, down $30.7M
- R&D expenses $100.9M vs $106.4M; G&A $24.4M vs $15.9M YoY
- Cash, cash equivalents and marketable securities expected to fund operations into Q1 2028; no cash-flow figures provided in excerpt
- Near-term outlook: z-rostudirsen BLA submission planned Q2 2026; tariffs pose potential supply-chain and cost headwinds
Risk Factors
- No newly triggered risk factor identified; the excerpt states ongoing risks without comparison to the prior 10-K
- Cash, cash equivalents and marketable securities $972.2 million, funding operations into the first quarter of 2028
- Loan Agreement includes a minimum cash covenant beginning January 1, 2027, initially set at 60% of outstanding obligations
- FDA clinical-hold risk for z-rostudirsen, following January 2022 requests for additional clinical and non-clinical information
- No approved products and no expected product commercialization before 2027, if ever
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Dyne Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.